What Happened?
Shares of genomics company Pacific Biosciences of California (NASDAQ: PACB) jumped 7.1% in the morning session after the company reported better-than-expected second-quarter 2025 financial results, beating revenue and earnings forecasts. The genomics company announced revenue of $39.77 million, a 10.4% increase year-over-year, which surpassed analysts' expectations by 7.6%. Its non-GAAP loss of $0.13 per share was also 21.5% narrower than anticipated. This performance was supported by a significant improvement in profitability, with the company's operating margin reaching negative 113%, a substantial improvement from negative 488% in the same quarter last year. The results suggest growing adoption of the company’s sequencing platforms, such as the Revio and Onso systems, which are used by researchers to analyze genomes with high accuracy.
Is now the time to buy PacBio? Access our full analysis report here, it’s free.
What Is The Market Telling Us
PacBio’s shares are extremely volatile and have had 88 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 10 days ago when the stock dropped 6.4% on the news that industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector. The core of the issue stems from an “unprecedented medical cost trend environment,” particularly within the Medicare Advantage market, which are privately run versions of the federal health insurance program. UnitedHealth, the largest provider in this space, now expects these costs to rise by 7.5% in 2025, a significant jump from its earlier 5% projection, with the potential to accelerate to almost 10% in 2026. In response, the insurer announced it will drop plans covering over 600,000 people. The company's lowered earnings forecast has raised investor concerns that these surging costs and utilization rates are an industry-wide problem, impacting the profitability of other carriers as well.
PacBio is down 24.8% since the beginning of the year, and at $1.35 per share, it is trading 48.9% below its 52-week high of $2.65 from November 2024. Investors who bought $1,000 worth of PacBio’s shares 5 years ago would now be looking at an investment worth $287.56.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
